Findings

What do systematic reviews say?

7 questions · 10 findings · 1 reviews · Headline outcomes only

No studies found 2 · 20%GRADE not reported 0 · 0%Very low 3 · 30%Low 3 · 30%Moderate 2 · 20%High 0 · 0%

Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Moderate

Adverse events related to treatment · non‐ambulatory children and adolescents with SMA types II and III

Oral olesoxime probably leads to lower adverse events related to treatment compared with placebo (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 0.95 [0.91, 0.99]
1 study · 165 participants
Moderate

Change in disability score · non‐ambulatory children and adolescents with SMA types II and III

4 findings from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Very low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Very low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.43
1 study · 160 participants
Very low

Show 1 more finding

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Low

Muscle strength · non‐ambulatory children and adolescents with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acquiring the ability to stand or walk · non‐ambulatory children and adolescents with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
Low

Change in pulmonary function · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Low